New drug combo aims to stop aggressive liver cancer from coming back

This study tests whether adding the drug lenvatinib before and after a standard tumor-burning procedure (ablation) can prevent liver cancer from returning in patients at high risk of recurrence. About 32 adults with early-stage liver cancer that has aggressive features (like high AFP levels or infiltrative tumors) will receive lenvatinib for 3 weeks before ablation and up to 12 weeks after. The main goal is to see if this approach improves the chance of being cancer-free one year later.